Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited has reported a significant year-on-year revenue increase of 257% to $4.59 million, with a 28% reduction in net loss to $4.5 million for the fiscal year ended March 31, 2024. Despite this progress, the company has decided not to issue dividends for the current financial year. Amplia, an Australian pharmaceutical firm, continues to develop its pipeline of FAK inhibitors for the treatment of cancer and fibrosis.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
